Show results for
Refine by
Cancer Screening Suppliers Serving Eritrea
52 companies found
based inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
based inRedwood City, CALIFORNIA (USA)
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. We’re developing blood tests for early detection in high-risk populations and ...
based inBensheim, GERMANY
We are a globally orientated German company with innovative products in the sector of point-of-care diagnostics and telemedical solutions that are used in clinics, practices and in everyone’s everyday life. Preventis GmbH was founded 2003 in ...
The immunological occult blood test PreventID® CC is a rapid test for self-testing for the qualitative detection of the valuable red blood pigment hemoglobin in stool as a marker for intestinal bleeding. The result can be read after 10 ...
based inIrvine, CALIFORNIA (USA)
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on ...
ConfirmMDx Addresses Prostate Biopsy Sampling Error and the False-Negative Biopsy Dilemma. “Rule-in” high-risk men who have had a previous negative biopsy result, may be harboring undetected cancer (a false-negative ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...
based inDunedin,, NEW ZEALAND
Pacific Edge is a cancer diagnostics company. We specialise in discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer. Our ...
Cxbladder is a non-invasive genomic urine test that quickly and accurately detects or rules out bladder cancer. The tests works at a molecular level, measuring five biomarker genes to detect the presence or absence of bladder cancer1, and comes as a ...
based inNotting Hill, AUSTRALIA
INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases to improve patient outcomes ...
INOVIQ’s NETs technology is a sample preparation platform with the potential to revolutionise the performance of liquid biopsy diagnostic assays. The market potential for liquid biopsy applications is estimated at billions of dollars ...
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique ...
based inValladolid, SPAIN
Founded in 2010, AMADIX is a leading molecular diagnostics company, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Our mission is to extend people’s lives by developing disruptive technologies ...
PreveCol, an innovative blood-based test for early colorectal cancer detection. PreveCol is an innovative test based on an algorithm that combines the clinical characteristics identified by Artificial Intelligence with the analysis of biomarker ...
based inBerlin, GERMANY
We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high ...
Colorectal cancer is curable in about 90% of cases if detected early. Nevertheless, this disease is one of the most frequent causes of cancer-related deaths in the industrialized world. Regular ...
based inVillejuif, FRANCE
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, ...
based inÜmraniye, TURKEY
Vitrosens Biotechnology is a high-tech company in Turkey founded for the development, manufacture, and delivery of in vitro diagnostic devices (IVD) to the world. Vitrosens Biotechnology headquartered in Turkey, by a group of entrepreneurs with a ...
Test kit qualitatively detects tumor marker Carcinoembryonic Antigen (CEA) in human serum, plasma, and whole blood ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...
based inNew Delhi, INDIA
Takara Bio companies provide kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, DSS Takara Bio India Private Ltd. is part of a company that holds ...
based inEspoo, FINLAND
We are a leading Finnish-based in vitro diagnostics (IVD) company established in 1974. We develop, manufacture, and distribute reliable and fast CE marked diagnostic tests for point of care. Our aim is to aid global health by promoting efficient ...
based inEatontown, NEW JERSEY (USA)
Immunostics offers a broad portfolio of performance-driven diagnostics solutions that provide more effective ways to assist in the diagnosis of a disease. Our products offer the right balance of science, technology and practicality across the ...
Greater sensitivity than traditional guaiac-based methods. Increased specificity to lower GI bleeding makes hema-screen SPECIFIC GOLD an ideal tool for colon cancer ...
based inPleasanton, CALIFORNIA (USA)
Anchor Molecular is a life science diagnostics company specializing in the development of best-in-class quality controls, reference materials, and reagents for liquid biopsy assays. We focus on liquid biopsy cancer diagnostic test based on cell-free ...
based inOsaka, JAPAN
Alfresa Pharma develops, manufactures, and sells diagnostic reagents and equipments used in hospital laboratories and group medical examinations, with the mission of “delivering unprecedented new in vitro diagnostics.” We have applied our original ...
The conventional fecal occult blood test uses a chemical to perform the test, such as guaiac test (g-FOBT). However, our FIT Hemoglobin and Trasnferrin products use an immunoassay that reacts specifically to human hemoglobin/transferrin, eliminating ...
based inRockville, MARYLAND (USA)
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development. By leveraging this expertise and combining it with advanced machine ...
20/20 GeneSystems developed PAULA’s Test, a blood test for early detection of lung cancer. It is available in the USA through licensed medical professionals. Testing is performed at 20/20’s CLIA licensed laboratory, ...
based inCortlandt Manor, NEW YORK (USA)
Polymedco is dedicated to enhancing early detection of life-threatening diseases as healthcare challenges intensify due to rising chronic disease rates, an aging population, and soaring medical costs. The company collaborates with healthcare ...
OC-Auto FIT is a fecal immunochemical test (FIT) designed to enhance colorectal cancer screening by offering a highly accurate and clinically supported method. The test is geared towards individuals aged 45 to 75, ...